A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male Volunteers
A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] PD-0332991 In Healthy Male Volunteers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Washington
-
Tacoma, Washington, United States, 98418
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A Healthy Male Volunteer between 18 and 55 years of age inclusive
- A Body Mass Index (BMI) of 17.5 to 30.5 kg/m2 and a total body weight >50kg
- A signed informed consent document
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular,hepatic,psychiatric, neurologic, or allergic disease.
- A positive urine drug or urine cotinine screen.
- Concurrent use of herbal or prescription medications or treatment with an investigational drug within 30 days or 5 half-lives preceding first dose of study medication.
- Subjects whose occupation requires exposure to radiation or monitoring of radiation exposure.
- Subjects with a history of irregular bowel movements (eg, regular episodes of diarrhea or constipation, irritable bowel syndrome (IBS) or lactose intolerance).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Radio-labeled Dose Arm
|
A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of [14C]-PD-0332991.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] of PD-0332991
Time Frame: 0-192 hrs
|
AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8).
It is obtained from AUC (0 - t) plus AUC (t - 8).
|
0-192 hrs
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PD-0332991
Time Frame: 0-192hrs
|
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
|
0-192hrs
|
|
Maximum Observed Plasma Concentration (Cmax) of PD-0332991
Time Frame: 1-24hrs
|
1-24hrs
|
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991
Time Frame: 1-24hrs
|
1-24hrs
|
|
|
Plasma Decay Half-Life (t1/2) of PD-0332991
Time Frame: 0-192hrs
|
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
|
0-192hrs
|
|
Apparent Oral Clearance (CL/F) of PD-0332991
Time Frame: 0-192hrs
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Clearance was estimated from population pharmacokinetic (PK) modeling.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
|
0-192hrs
|
|
Apparent Volume of Distribution (Vz/F) of PD-0332991
Time Frame: 0-192hrs
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
|
0-192hrs
|
|
Cumulative radioactivity recovery in urine.
Time Frame: 0-192hrs
|
Cumulative radioactivity recovered in urine is the percent of the administered radioactive dose that is observed in the cumulative urine samples.
|
0-192hrs
|
|
Cumulative radioactivity recovery in feces.
Time Frame: 0-192hrs
|
Cumulative radioactivity recovered in fecal is the percent of the administered radioactive dose that is observed in the cumulative fecal samples.
|
0-192hrs
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] of PF-05089326.
Time Frame: 0-192hrs
|
AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8).
It is obtained from AUC (0 - t) plus AUC (t - 8).
|
0-192hrs
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-05089326.
Time Frame: 0-192hrs
|
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
|
0-192hrs
|
|
Maximum Observed Plasma Concentration (Cmax) of PF-05089326.
Time Frame: 0-192hrs
|
0-192hrs
|
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-05089326.
Time Frame: 0-192hrs
|
0-192hrs
|
|
|
Plasma Decay Half-Life (t1/2) of PF-05089326.
Time Frame: 0-192hrs
|
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
|
0-192hrs
|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)] of radioactivity in plasma.
Time Frame: 0-192hrs
|
AUC (0 - 8)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0 - 8).
It is obtained from AUC (0 - t) plus AUC (t - 8).
|
0-192hrs
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of radioactivity in plasma.
Time Frame: 0-192hrs
|
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
|
0-192hrs
|
|
Maximum Observed Concentration (Cmax) of radioactivity in plasma.
Time Frame: 0-192hrs
|
0-192hrs
|
|
|
Time to Reach Maximum Observed Concentration (Tmax) of radioactivity in plasma.
Time Frame: 0-192hrs
|
0-192hrs
|
|
|
Plasma Decay Half-Life (t1/2) of radioactivity in plasma.
Time Frame: 0-192hrs
|
Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.
|
0-192hrs
|
|
Apparent Oral Clearance (CL/F) of radioactivity in plasma.
Time Frame: 0-192hrs
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.
Clearance was estimated from population pharmacokinetic (PK) modeling.
Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood.
|
0-192hrs
|
|
Apparent Volume of Distribution (Vz/F) of radioactivity in plasma.
Time Frame: 0-192 hrs
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.
Apparent volume of distribution after oral dose (Vz/F) is influenced by the fraction absorbed.
|
0-192 hrs
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A5481011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.